Navigation Links
SpectraScience CEO Jim Hitchin Featured in Interview With The Wall Street Transcript
Date:5/6/2009

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego-based medical device company, today announced that The Wall Street Transcript has published an in-depth interview with Chief Executive Officer Jim Hitchin. The interview, in its entirety, is available on the company's website at http://www.spectrascience.com/tinymce/jscripts/tiny_mce/plugins/ajaxfilemanager/uploaded/Wall%20Street%20Transcript.pdf

Mr. Hitchin said, "Each year there are literally hundreds of thousands of cases of colorectal, cervical and esophageal cancer which, because they are not diagnosed or caught early enough, result in higher mortality rates and higher costs. Our technology enables physicians to more accurately diagnose these diseases, and to do so at an earlier stage. This is critical to reducing deaths from cancer and to reducing overall costs to the healthcare system."

SpectraScience's technology provides the healthcare community with the promise of a higher degree of objectivity and sensitivity in the cancer screening process for colon cancer and cervical cancer. It is also undergoing clinical trials for an esophageal cancer screening application.

During the interview, Mr. Hitchin also reiterated that the company is focusing all resources in sales, adding that it has a competitive advantage from a technology standpoint and that there are no direct competitors to its cancer screening platforms. He emphasized that the chance to detect cancers early, or much earlier than is currently the case, means more people are going to live longer.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

    Contact:
    SpectraScience, Inc.                     Investor Relations
    Jim Hitchin, Chief Executive Officer     Hayden Communications
    (858) 847-0200  x 201                    Todd Pitcher
                                             (858)-518-1387

                                             Media Relations
                                             Gitenstein & Assadi PR
                                             Susan Assadi
                                             (800) 922-8792


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis
2. SpectraScience Strengthens Leadership Team With Four Key Hires
3. Jim Dorst Joins SpectraScience as CFO
4. SpectraScience Appoints the Honorable Tommy Thompson to its Board of Directors
5. Bio-Matrix Scientific Group Featured as Stock Pick in Oakleys Column on WallStreetCorner.com
6. Histogen Featured on Economic Report Television Series
7. Imaging Diagnostic Systems CT Laser Mammography (CTLM) Technology Featured in Peer-Reviewed Journal
8. Imaging Diagnostic Systems CT Laser Mammography (CTLM(R)) System Featured at the 94th Annual Radiological Society of North America (RSNA) Conference
9. BOXX Personal Supercomputer for Research Scientists Featured at SC08
10. ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting
11. Former Speaker of the House Newt Gingrich Featured Wednesday
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017  Asterias Biotherapeutics, Inc. ... field of regenerative medicine, today announced positive efficacy ... clinical trial that showed additional motor function improvement ... million AST-OPC1 cells in AIS-A patients with complete ... of upper extremity motor function is critically important ...
(Date:1/24/2017)... Switerland (PRWEB) , ... January 24, 2017 , ... ... first commercially available malaria Plasmodium falciparum culture panels with standard concentrations of histidine ... which are available in a range of concentrations from six different malaria strains, ...
(Date:1/24/2017)... , ... January 23, 2017 , ... Oklahoma City based ... newest client for the firm’s PERFEQTA software and legacy product QC Manager 2.0. ... the dynamic team at CJBC and thrilled that they have decided to implement PERFEQTA ...
(Date:1/24/2017)... , Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... into an underwriting agreement with Rodman & Renshaw, a ... as sole book running manager and representative of several underwriters, ... a firm commitment basis a minimum of 2,105,264 shares ... to purchase a minimum of 1,052,632 shares of common ...
Breaking Biology Technology:
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/12/2017)... Jan. 12, 2017  New research undertaken by Fit ... the future.  1,000 participants were simply asked which office technology ... we may consider standard issue.  Insights on what will ... also gathered from futurists and industry leaders including Penelope ... Canton .  Some of these findings ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):